Picture of Prestige Biologics Co logo

334970 Prestige Biologics Co Cashflow Statement

0.000.00%
kr flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Annual cashflow statement for Prestige Biologics Co, fiscal year end - June 30th, KRW millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
June 30th
2024
June 30th
2025
June 30th
Period Length:12 M12 M6 M12 M12 M
Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-39,378-49,718-17,980-29,374-27,469
Depreciation
Amortisation
Non-Cash Items32,45319,83511,157-9,771-2,764
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital-22,865-12,245-1,87019,569-1,176
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities-25,869-34,190-4,450-8,345-18,327
Capital Expenditures-98,011-84,790-19,495-8,637-5,656
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items1011,12418.271197.7
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities-97,910-83,665-19,477-7,927-5,558
Financing Cash Flow Items-28.4-42.7-52.3-51.2
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities156,31296,46353,979345-4,041
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash32,533-21,39230,052-15,928-27,926
0